{
  "paper_id": "PMC11969261",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969261/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Schematic outlining the selection process of MDS trials. A total of 464 trials were selected for further screening after initial search results; 191 trials were included in the final analysis. Most trials incorporated MDS with AML.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/fce3778fdac6/BLOOD_BLD-2023-023717-gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/fce3778fdac6/BLOOD_BLD-2023-023717-gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/fce3778fdac6/BLOOD_BLD-2023-023717-gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/fce3778fdac6/BLOOD_BLD-2023-023717-gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/fce3778fdac6/BLOOD_BLD-2023-023717-gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11969261/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/fce3778fdac6/BLOOD_BLD-2023-023717-gr1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Most common inclusion criteria in early-phase vs late-phase trials. There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/6216700d3947/BLOOD_BLD-2023-023717-gr2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/6216700d3947/BLOOD_BLD-2023-023717-gr2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/6216700d3947/BLOOD_BLD-2023-023717-gr2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/6216700d3947/BLOOD_BLD-2023-023717-gr2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/6216700d3947/BLOOD_BLD-2023-023717-gr2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11969261/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/6216700d3947/BLOOD_BLD-2023-023717-gr2.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Most common exclusion criteria in early-phase vs late-phase trials. There is a significant difference between early- and late-phase trials for exclusion criteria categorized as liver function tests, chronic viral illness, and prior treatments.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/b860a261888f/BLOOD_BLD-2023-023717-gr3.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/b860a261888f/BLOOD_BLD-2023-023717-gr3.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/b860a261888f/BLOOD_BLD-2023-023717-gr3.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/b860a261888f/BLOOD_BLD-2023-023717-gr3.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/b860a261888f/BLOOD_BLD-2023-023717-gr3.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11969261/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/b860a261888f/BLOOD_BLD-2023-023717-gr3.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Overall concordance and discordance of eligibility criteria with drug safety signals. A safety signal (SS) is defined as the presence of a potential drug safety issue as identified by literature and pharmacist review. A limit is defined as eligibility criteria that is restrictive. The presence or absence of SS and limits for the following variables in each trial were assessed: EF, QTc limits, HIV, hepatitis B, hepatitis C, creatinine, ALT, AST, and total bilirubin. Stacked bars show concordance (shades of blue) and discordance (red and orange) between eligibility criteria and relevant drug safety signals. Numbers within the bars indicate the number of trials.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/7a772f27be58/BLOOD_BLD-2023-023717-gr4.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/7a772f27be58/BLOOD_BLD-2023-023717-gr4.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/7a772f27be58/BLOOD_BLD-2023-023717-gr4.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/7a772f27be58/BLOOD_BLD-2023-023717-gr4.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/7a772f27be58/BLOOD_BLD-2023-023717-gr4.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11969261/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/271d/11969261/7a772f27be58/BLOOD_BLD-2023-023717-gr4.jpg"
    }
  },
  "claims": [
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The survey was updated with recurrent ideas and distributed in round 2 for final consensus, and ≥75% agreement resulted in a recommendation.Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Results\nCharacteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Specified baseline disease characteristics within selected trials\n\n\nMDS disease status\nNo. of trials\n\n\n\nLower risk only\n38\n\n\nHigher risk only\n110\n\n\nLower and higher risk\n14\n\n\nTreatment naïve\n12\n\n\nRelapsed/refractory\n86\n\n\nTreatment naïve and relapsed/refractory\n27\n\n\n\nOpen in a new tabEligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Overall, 23 trials had safety data incorporated from online publications.Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Characteristics of clinical trials\nOur initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Most trials incorporated MDS with AML.Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Our initial search yielded 464 trials of which 191 were included for analysis after screening as shown in Figure 1; 273 trials were excluded from additional analyses as outlined in Methods.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Trials most commonly included MDS and AML (n = 74); followed by MDS only (n = 60); MDS, AML, and CMML (n = 30); then MDS and CMML (n = 27; Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Eligibility criteria\nThe most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "There is a significant difference between early- and late-phase trials for inclusion criteria categorized as expected survival, bone marrow blasts, transfusion requirements, and washout periods.The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The most common inclusion criteria were performance status, age, disease risk stratification system, prior treatments, transplant status, expected survival, bone marrow blasts, transfusion requirements, washout periods, and baseline platelets (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The following categories were the most common exclusion criteria (Figure 3): cardiac disease, uncontrolled infection, pregnancy/breastfeeding, creatinine or creatinine clearance, liver function tests, chronic viral illness, washout periods, prior treatments, other malignancies, and gastrointestinal disorders.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Concordance\nWe evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We evaluated the concordance (blue) and discordance (red and orange) of criteria with known drug safety data available for ALT/AST, total bilirubin, HIV, hepatitis B, hepatitis C, EF, and QTc (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 4,
    "claims_count": 55,
    "images_downloaded": 4,
    "tables_filtered": 65
  }
}